Description: |
This phase III trial is studying everolimus to see how well it works in treating patients with kidney cancer who have full surgical resection. Patients must have histologically or cytologically confirmed renal cell carcinoma (clear cell or non-clear cell allowed, collecting duct or medullary carcinoma excluded). Patients must be considered pathologically either intermediate high risk or very high risk. Patients must not have history of distant metastases but can have microvascular invasion of the renal vein of any grade or stage (as long as M0). Patients must have undergone a full surgical resection (radical nephrectomy or partial nephrectomy) including removal of all clinically positive nodes. Surgical margins must be negative. Patient must not have any evidence of residual or metastatic RCC on scans after nephrectomy. |
Link: |
Trial for patients with renal cell cancer following full surgical resection |
Site: |
George Washington University-Medical Faculty Associates |
Principal Investigator: |
Jeanny Aragon-Ching, M.D. |